Similar articles

• Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.

  Bingham CO 3rd, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, Smugar SS, Fitzgerald BJ, O'Brien K, Tershakovec AM. Bingham CO 3rd, et al. Rheumatology (Oxford). 2007 Mar;46(3):496-507. doi: 10.1093/rheumatology/kel296. Epub 2006 Aug 27. Rheumatology (Oxford). 2007. PMID: 16936327 Clinical Trial.
• Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo.

  Bingham CO 3rd, Smugar SS, Wang H, Tershakovec AM. Bingham CO 3rd, et al. Rheumatology (Oxford). 2009 Sep;48(9):1122-7. doi: 10.1093/rheumatology/kep184. Epub 2009 Jul 9. Rheumatology (Oxford). 2009. PMID: 19589894
• Clinical inquiries. Do COX-2 inhibitors worsen renal function?

  Wall R, Strickland C, Jamieson B, Lo V. Wall R, et al. J Fam Pract. 2007 Nov;56(11):957-8. J Fam Pract. 2007. PMID: 17976347 No abstract available.
• [The efficacy of selective Cox-2-inhibitors in comparison with conventional NSAIDs].

  Krüger K. Krüger K. MMW Fortschr Med. 2005 Aug 4;147(31-32):28-30. MMW Fortschr Med. 2005. PMID: 16128193 Review. German.
• Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan.

  Sakamoto C, Soen S. Sakamoto C, et al. Digestion. 2011;83(1-2):108-23. doi: 10.1159/000318746. Epub 2010 Nov 1. Digestion. 2011. PMID: 21042022 Review.